Want to see SE:ATORX full AI Analyst Report?
Alligator Bioscience AB (ATORX) AI Stock Analysis
Alligator Bioscience AB
(Nasdaq OMX AB:ATORX)
The stock scores at the absolute minimum of 37, reflecting a state of extreme financial distress. The most significant factor is the company's near-total revenue collapse and accelerating cash burn, which has eroded shareholder equity and created an unsustainable capital structure. This is compounded by a deeply bearish technical trend with the stock trading below all key moving averages and in oversold territory. The negative P/E ratio confirms a complete lack of earnings power. The company faces an imminent liquidity crisis, posing an exceptionally high risk of total loss for equity holders.
Alligator Bioscience AB (ATORX) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 35.32M
- Dividend Yield
- ―
- Average Volume (3M)
- 22.88M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 0.97
- Revenue Growth
- -99.33%
- EPS Growth
- 64.90%
- Country
- Sweden
- Employees
- 11
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Alligator Bioscience AB Business Overview & Revenue Model
Company Description
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its dru...
How the Company Makes Money
Alligator Bioscience primarily generates or seeks to generate revenue through: (1) out-licensing and partnering its drug candidates and underlying antibody discovery/optimization capabilities to larger pharmaceutical or biotech companies in exchange...
Alligator Bioscience AB Financial Statement Overview
Summary
Financial health is critically poor. Revenue has collapsed to near zero, net losses are massive and persistent, the balance sheet is highly leveraged with a recently negative equity base, and operating cash burn is accelerating with no path to self-sufficiency. This represents an extreme risk to viability.
Income Statement
8Very NegativeBalance Sheet
10Very NegativeCash Flow
5Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 283.00K | 514.00K | 57.77M | 58.11M | 35.70M | 12.94M |
| Gross Profit | -38.25M | -54.82M | 57.77M | 58.11M | -112.03M | -74.04M |
| EBITDA | -95.92M | -121.98M | -165.47M | -237.61M | -180.99M | -130.36M |
| Net Income | -82.10M | -51.35M | -233.89M | -248.59M | -193.40M | -141.74M |
Balance Sheet | ||||||
| Total Assets | 89.41M | 110.60M | 104.34M | 118.45M | 169.58M | 333.20M |
| Cash, Cash Equivalents and Short-Term Investments | 41.25M | 62.20M | 64.31M | 66.12M | 97.31M | 278.15M |
| Total Debt | 27.78M | 43.15M | 43.57M | 16.10M | 24.50M | 9.74M |
| Total Liabilities | 66.23M | 103.74M | 234.93M | 106.59M | 80.53M | 50.93M |
| Stockholders Equity | 23.17M | 6.86M | -130.59M | 11.86M | 89.05M | 282.27M |
Cash Flow | ||||||
| Free Cash Flow | -97.31M | -157.45M | -212.43M | -191.74M | -173.05M | -127.08M |
| Operating Cash Flow | -97.31M | -155.99M | -212.43M | -189.28M | -172.61M | -127.03M |
| Investing Cash Flow | 0 | 2.21M | 0 | -2.46M | -440.00K | -45.00K |
| Financing Cash Flow | 113.70M | 152.59M | 211.27M | 161.56M | -7.83M | 301.80M |
Alligator Bioscience AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ATORX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 24.27 is Positive, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ATORX.
Alligator Bioscience AB Peers Comparison
Overall Rating
SE:CANTA70Outperform
SE:ELIC48Neutral
SE:ONCO47Neutral
SE:BINV43Neutral
SE:IMMU43Neutral- SE:ATORX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CANTA | 70Outperform | SEK 451.68M | 2.35 | 63.09% | ― | ― | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| SE:ELIC | 48Neutral | SEK 177.19M | -7.51 | -56.09% | ― | ― | 14.10% |
| SE:ONCO | 47Neutral | SEK 721.66M | -2.14 | ― | ― | 87.23% | 35.27% |
| SE:BINV | 43Neutral | SEK 357.32M | -0.73 | -128.54% | ― | -83.67% | -50.29% |
| SE:IMMU | 43Neutral | SEK 348.89M | -3.07 | -18.05% | ― | ― | 15.97% |
| SE:ATORX | 37Underperform | SEK 35.32M | -0.01 | -439.98% | ― | -99.33% | 64.90% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ATORX | Alligator Bioscience AB | 0.01 | -0.38 | -97.42% | |
| SE:BINV | BioInvent International AB | 5.43 | -28.47 | -83.98% | |
| SE:ONCO | Oncopeptides AB | 1.67 | -3.75 | -69.16% | |
| SE:ELIC | Elicera Therapeutics AB | 2.65 | -3.44 | -56.47% | |
| SE:IMMU | Immunicum AB | 5.50 | -1.89 | -25.58% | |
| SE:CANTA | Cantargia AB | 1.60 | -1.97 | -55.13% |
Alligator Bioscience AB Corporate Events
Alligator Bioscience Plans 1-for-1,000 Reverse Share Split and Warrant Term Adjustments
Alligator Bioscience AB plans to seek shareholder approval at an Extraordinary General Meeting on 27 November 2026 for a 1-for-1,000 reverse split of its ordinary shares, consolidating the total number from about 3.57 billion to roughly 3.57 million...
Alligator Bioscience Calls Extraordinary Meeting to Restructure Share Capital and Board
Alligator Bioscience AB has called an extraordinary general meeting for 27 November 2026 in Lund, Sweden, inviting shareholders to vote on a series of corporate actions. The meeting will address share capital restructuring measures, board composition...
Alligator Bioscience Refocuses Strategy on HLX22 and Bolsters Finances
Alligator Bioscience has undertaken a strategic refocus in the third quarter of 2026, discontinuing independent development of its lead asset mitazalimab and concentrating on its financial interest in HLX22, which is advancing through global Phase 3...
Alligator Bioscience to Present Q3 HER2-Focused Interim Report on 22 October
Alligator Bioscience will publish its interim report for the July–September 2026 period, focused on its HER2-targeting activities, on 22 October 2026 at 8:00 a.m. CEST. The company will the same day host an English-language webinar and conferen...
Alligator Bioscience Names CFO Johan Giléus as CEO Amid Strategic Refocus on HLX22
Alligator Bioscience has appointed its current Chief Financial Officer, Johan Giléus, as Chief Executive Officer effective 1 January 2027, succeeding Søren Bregenholt, who will remain in the role until the end of 2026 to ensure a smooth han...
Alligator Bioscience Restructures Fenja Loan With Directed Warrant Issue
Alligator Bioscience has issued 187,795,097 warrants to Fenja Capital as part of a renegotiated loan arrangement linked to its recently completed rights issue. The new 2026/2031 warrants, replacing an earlier 2025/2030 series, correspond to about 5 p...
Alligator Bioscience’s Rights Issue Heavily Reliant on Guarantees, Triggers Major Dilution
Alligator Bioscience has reported the final outcome of its rights issue of units, in which only about 17.1 percent of the maximum 3.14 billion units were subscribed by investors, with the remainder largely covered by guarantee commitments. Each unit...
Alligator Bioscience’s Rights Issue Undersubscribed, Underwriters Step In
Alligator Bioscience AB has reported the preliminary outcome of its rights issue of units, launched in July 2026, with subscriptions totaling about 17.1 percent through exercise of unit rights and 16.7 percent without rights. This level of demand mea...
Alligator Bioscience Launches SEK 125.6 Million Rights Issue to Refocus Oncology Pipeline
Alligator Bioscience has published a prospectus for a rights issue of up to 3,140,534,240 units, each comprising two shares and two series of warrants, at a subscription price of SEK 0.04 per unit. The offer, running from 4 to 18 September 2026, coul...
Alligator Bioscience Restructures Capital and Launches Major Rights Issue
Alligator Bioscience’s extraordinary general meeting approved multiple changes to its capital structure, including amendments to the Articles of Association and significant reductions of share capital to cover losses and reallocate funds to unr...
Alligator Bioscience exits mitazalimab development to refocus on HLX22 royalties and recapitalisation
Alligator Bioscience reported a weak second quarter with no significant operational events, continuing to post operating losses and declining cash, while progressing investigator-led studies and data presentations for mitazalimab and highlighting enc...
Alligator Bioscience Schedules August Earnings Call Amid Strategic Refocus
Alligator Bioscience will publish its interim report for the April–June 2026 period related to its HER2-targeting activities on 26 August 2026. On the same day, the company will host an earnings webinar and conference call in English, led by CE...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026